Functional and phenotypic characterization of virus-specific CD8 T cells against cytomegalovirus, Epstein-Barr virus, influenza (flu), and HIV-1 were performed on the basis of the ability of CD8 T cells to secrete IFN-γ and IL-2, to proliferate, and to express CD45RA and CCR7. Two functional distinct populations of CD8 T cells were identified: (
i
) dual IFN-γ/IL-2-secreting cells and (
ii
) single IFN-γ-secreting cells. Virus-specific IFN-γ/IL-2-secreting CD8 T cells were CD45RA
-
CCR7
-
, whereas single IFN-γ CD8 T cells were either CD45RA
-
CCR7
-
or CD45RA
+
CCR7
-
. The proportion of virus-specific IFN-γ/IL-2-secreting CD8 T cells correlated with that of proliferating CD8 T cells, and the loss of HIV-1-specific IL-2-secreting CD8 T cells was associated with that of HIV-1-specific CD8 T cell proliferation. Substantial proliferation of virus-specific CD8 T cells (including HIV-1-specific CD8 T cells) was also observed in CD4 T cell-depleted populations or after stimulation with MHC class I tetramer-peptide complexes. IL-2 was the factor responsible for the CD4-independent CD8 T cell proliferation. These results indicate that IFN-γ/IL-2-secreting CD8 T cells may promote antigen-specific proliferation of CD8 T cells even in the absence of helper CD4 T cells.
B cell proliferation, cytokine release, and plasmablast differentiation assays CD19 + B cells were isolated from PBMCs of healthy volunteers by negative selection using the B cell purification kit II (Miltenyi Biotec,
Thymic stromal lymphopoietin (TSLP) is an IL-7–related cytokine, produced by epithelial cells, that has been linked to atopic dermatitis and asthma; however, it remains unclear how TSLP shapes the adaptive immune response that causes these allergic disorders. In this study, we demonstrate a role for TSLP in a Th2 model of contact hypersensitivity in mice. TSLP is required for the development of Th2-type contact hypersensitivity induced by the hapten FITC in combination with the sensitizing agent dibutyl phthalate. TSLPR-deficient mice exhibited a dramatically reduced response, including markedly reduced local infiltration by eosinophils, Th2 cytokine production, and serum IgE levels, following FITC sensitization and challenge. The reduced response by TSLPR-deficient mice is likely due to decreased frequency and reduced T cell stimulatory function of skin-derived Ag-bearing FITC+CD11c+ dendritic cells in draining lymph nodes following FITC sensitization. These data suggest that skin-derived dendritic cells are direct or indirect targets of TSLP in the development of type 2 immune responses in the skin, where TSLP drives their maturation, accumulation in skin draining lymph nodes, and ability to induce proliferation of naive allergen-specific T cells.
Bruton’s
tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent
role in the treatment of B cell malignancies. However, further refinement
is needed to this class of agents, particularly in terms of adverse
events (potentially driven by kinase promiscuity), which preclude
their evaluation in nononcology indications. Here, we report the discovery
and preclinical characterization of evobrutinib, a potent, obligate
covalent inhibitor with high kinase selectivity. Evobrutinib displayed
sufficient preclinical pharmacokinetic and pharmacodynamic characteristics
which allowed for in vivo evaluation in efficacy models. Moreover,
the high selectivity of evobrutinib for BTK over epidermal growth
factor receptor and other Tec family kinases suggested a low potential
for off-target related adverse effects. Clinical investigation of
evobrutinib is ongoing in several autoimmune diseases, including multiple
sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.